A four immune-related long noncoding RNAs signature as predictors for cervical cancer

被引:0
作者
Min Xu
Runjie Zhang
Jin Qiu
机构
[1] Tongren Hospital,Hongqiao International Institute of Medicine
[2] Shanghai Jiao Tong University School of Medicine,Obstetrics and Gynecology Department
[3] Tongren Hospital,undefined
[4] Shanghai Jiao Tong University School of Medicine,undefined
来源
Human Cell | 2022年 / 35卷
关键词
Cervical cancer; Long non-coding RNA; Immune-related lncRNAs; Prognostic; Predicted model;
D O I
暂无
中图分类号
学科分类号
摘要
The progression, metastasis, and prognosis of cervical cancer (CC) is influenced by the tumor immune microenvironment. Studies proved that long non-coding RNAs (lncRNAs) to engage in cervical cancer development, especially immune-related lncRNAs, have emerged crucial in the tumor immune process. This study was set out to identify an immune-related lncRNA signature. In total, 13,838 lncRNA expression profiles and 328 immune genes were acquired from the clnical data of 306 CC tissues and 3 non-CC tissues. From the 433 identified immune-related lncRNAs, 4 candidate immune-related lncRNAs (SOX21-AS1, AC005332.4, NCK1-DT, LINC01871) were considered independent indicators of cervical cancer prognosis through the univariate and multivariate Cox regression analysis, and they were used to construct a prognostic and survival lncRNA signature model followed by the bootstrap method for further verification. Kaplan–Meier curves illustrated that cervical cancer patients could be divided into high-risk and low-risk groups with significant differences (P = 2.052e − 05), and the discrepancy of immune profiles between these two risk groups was illustrated by principal components analysis. Taken together, the novel survival predictive model created by the four immune-related lncRNAs showed promising clinical prediction value in cervical cancer.
引用
收藏
页码:348 / 359
页数:11
相关论文
共 380 条
[1]  
Cohen P(2019)Cervical cancer Lancet (London, England) 393 169-182
[2]  
Jhingran A(2020)Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes Clin Exp Metas 37 107-113
[3]  
Oaknin A(2014)New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy Clin cancer res: off j Am Assoc Cancer Res 20 5349-5358
[4]  
Denny L(2020)Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity EBioMedicine 57 102841-608
[5]  
Gardner A(2020)Peripheral blood circulating microRNA-4636/-143 for the prognosis of cervical cancer J Cell Biochem 121 596-2292
[6]  
Charo L(2020)Association of MRI-derived radiomic biomarker with disease-free survival in patients with early-stage cervical cancer Theranostics 10 2284-734
[7]  
Mann A(2017)The immune contexture in cancer prognosis and treatment Nat Rev Clin Oncol 14 717-44
[8]  
Kapp D(2020)The hypoxic tumour microenvironment: a safe haven for immunosuppressive cells and a therapeutic barrier to overcome Cancer Lett 487 34-1100
[9]  
Eskander R(2020)Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic Cancer Treat Rev 89 102067-7777
[10]  
Chan J(2020)Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model Br J Cancer 123 1089-796